Limits...
A Multicenter, Single-Blind Randomized, Controlled Study of a Volumizing Hyaluronic Acid Filler for Midface Volume Deficit: Patient-Reported Outcomes at 2 Years.

Few J, Cox SE, Paradkar-Mitragotri D, Murphy DK - Aesthet Surg J (2015)

Bottom Line: The effectiveness of Juvéderm Voluma XC was examined from the patient perspective.Increased satisfaction with outer and lower cheek areas and cheek-bone projection and clinically significant improvements in LAFM were noted through month 24.Juvéderm Voluma XC for age-related MVD is effective and well-tolerated from the patient perspective, with results lasting up to 2 years. 4 Therapeutic.

View Article: PubMed Central - PubMed

Affiliation: Dr Few is Clinical Professor of Surgery, Division of Plastic Surgery, University of Chicago Pritzker School of Medicine, Chicago, Illinois. Dr Cox is Assistant Clinical Professor, University of North Carolina, Chapel Hill, North Carolina; and is Supervising Physician, Dermatology Program, Duke University, Durham, North Carolina. Dr Paradkar-Mitragotri was the Manager of Biostatistics at the time of this study and is a former employee of Allergan, Inc., Irvine, California, and Ms Murphy is the Director of Clinical Development Submissions at Allergan, Inc., Irvine, California.

No MeSH data available.


Related in: MedlinePlus

Percentage of patients reporting that their perceived age was younger than their chronological age, older, or the same compared with baseline at 6 (A), 12 (B), and 24 (C) months after treatment.
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4482214&req=5

SJV050F7: Percentage of patients reporting that their perceived age was younger than their chronological age, older, or the same compared with baseline at 6 (A), 12 (B), and 24 (C) months after treatment.

Mentions: At each time point following treatment with Juvéderm Voluma XC, a majority of patients perceived themselves as looking younger versus baseline, from 72.5% at month 6 to 55.4% at month 24 (Figure 7). The mean decrease in perceived age was 4.9 years at month 6, 3.8 years at month 12, and 3.3 years at month 24.Figure 7.


A Multicenter, Single-Blind Randomized, Controlled Study of a Volumizing Hyaluronic Acid Filler for Midface Volume Deficit: Patient-Reported Outcomes at 2 Years.

Few J, Cox SE, Paradkar-Mitragotri D, Murphy DK - Aesthet Surg J (2015)

Percentage of patients reporting that their perceived age was younger than their chronological age, older, or the same compared with baseline at 6 (A), 12 (B), and 24 (C) months after treatment.
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4482214&req=5

SJV050F7: Percentage of patients reporting that their perceived age was younger than their chronological age, older, or the same compared with baseline at 6 (A), 12 (B), and 24 (C) months after treatment.
Mentions: At each time point following treatment with Juvéderm Voluma XC, a majority of patients perceived themselves as looking younger versus baseline, from 72.5% at month 6 to 55.4% at month 24 (Figure 7). The mean decrease in perceived age was 4.9 years at month 6, 3.8 years at month 12, and 3.3 years at month 24.Figure 7.

Bottom Line: The effectiveness of Juvéderm Voluma XC was examined from the patient perspective.Increased satisfaction with outer and lower cheek areas and cheek-bone projection and clinically significant improvements in LAFM were noted through month 24.Juvéderm Voluma XC for age-related MVD is effective and well-tolerated from the patient perspective, with results lasting up to 2 years. 4 Therapeutic.

View Article: PubMed Central - PubMed

Affiliation: Dr Few is Clinical Professor of Surgery, Division of Plastic Surgery, University of Chicago Pritzker School of Medicine, Chicago, Illinois. Dr Cox is Assistant Clinical Professor, University of North Carolina, Chapel Hill, North Carolina; and is Supervising Physician, Dermatology Program, Duke University, Durham, North Carolina. Dr Paradkar-Mitragotri was the Manager of Biostatistics at the time of this study and is a former employee of Allergan, Inc., Irvine, California, and Ms Murphy is the Director of Clinical Development Submissions at Allergan, Inc., Irvine, California.

No MeSH data available.


Related in: MedlinePlus